Roche and Promega set date for PCR court case
This article was originally published in Clinica
A date has been set early next year for the long-running Roche PCR intellectual property case. The other party in the US court action, Promega, claims that a result in its favour could see the Swiss company lose control of PCR technology and the licence revenue it produces.
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.